Exact Sciences Corp. stock (US30063P1057): Q4 earnings miss with revenue up 23%

Exact Sciences Corp. reported Q4 earnings of -$0.21 per share, missing estimates by $0.29, though revenue grew 23.1% year-over-year, per MarketBeat data from February 13.

Exact Sciences Corp. (NASDAQ:EXAS), a leader in cancer screening and diagnostics, released its latest quarterly earnings on February 13, 2026. The company posted earnings per share of -$0.21, falling short of the consensus estimate of $0.08 by $0.29. Revenue for the quarter rose 23.1% year-over-year, reflecting continued demand for its precision oncology tests, MarketBeat as of February 13, 2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Exact Sciences Corporation
• Sector/industry: Healthcare / Diagnostics
• Headquarters/country: United States
• Core markets: US, Europe
• Key revenue drivers: Cologuard, Oncotype DX
• Home exchange/listing venue: Nasdaq (EXAS)
• Trading currency: USD

Exact Sciences Corp.: core business model

Exact Sciences Corp. specializes in non-invasive cancer screening and diagnostic testing. Its flagship product, Cologuard, is a stool-based DNA test for colorectal cancer screening approved by the FDA. The company also offers Oncotype DX, a genomic test assessing breast cancer recurrence risk to guide treatment decisions. These products target the growing precision medicine market, with Cologuard driving the majority of revenue through direct-to-consumer and physician channels in the US.

Operations focus on laboratory services, with CLIA-certified labs processing samples. The business model emphasizes recurring revenue from repeat screenings, as guidelines recommend colorectal cancer checks every three years for average-risk patients. Exact Sciences invests heavily in marketing and sales to expand screening adoption, particularly among underserved populations.

Main revenue and product drivers for Exact Sciences Corp.

Cologuard remains the primary revenue driver, accounting for over 80% of sales in recent quarters reported for 2025. The test's completed lives metric—representing patients who finish screening—grew steadily, supporting the 23.1% revenue increase in Q4 2025 published February 13, 2026. Oncotype DX contributes through partnerships with major oncology centers, with volume tied to breast cancer diagnosis rates.

International expansion into Europe via partnerships adds incremental growth, though the US remains core. R&D spending supports pipeline tests like multi-cancer detection tools, aiming to diversify beyond colorectal screening. For Q4 2025 per MarketBeat as of February 13, 2026, net margins stood at -6.40%, reflecting high growth investments.

Industry trends and competitive position

The diagnostics sector benefits from rising cancer incidence and screening awareness in the US, where colorectal cancer is the second-leading cause of cancer death. Competitors include Guardant Health and Natera in liquid biopsy, but Exact Sciences holds a strong moat with Cologuard's first-mover status and Medicare coverage. Market penetration remains below 10% of eligible US patients, offering runway for growth.

Why Exact Sciences Corp. matters for US investors

Listed on Nasdaq, Exact Sciences provides US investors exposure to the $10B+ US cancer screening market. Its tests align with preventive healthcare trends under Medicare and private insurance, bolstered by ACA mandates. Revenue sensitivity to US healthcare spending makes it relevant amid policy debates on drug pricing and diagnostics reimbursement.

Conclusion

Exact Sciences Corp. demonstrated revenue growth in its Q4 2025 results despite an earnings miss, underscoring execution in screening volume amid competitive pressures. Investors track progress on profitability and international scaling. The stock's trajectory hinges on adoption metrics and reimbursement dynamics in the US healthcare landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.